Related Experiment Video
Updated: Feb 17, 2026

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
Published on: October 14, 2025
The Experience with Biosimilars of Infliximab in Inflammatory Bowel Disease
Pedro Avila-Ribeiro1, Gionata Fiorino2,3, Silvio Danese2,3
1Rheumatology and Metabolic Bone Diseases Department, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisbon Academic Medical Centre, Lisbon, Portugal.
Background:
biosimilars are similar versions of existing innovator biologic agents but with distinct manufacturing processes. They were approved in inflammatory bowel disease (IBD) by extrapolation of indication from rheumatic diseases. As regulatory requirements for biosimilar approval focus on pre-clinical evidence of similarity rather than clinical data on efficacy, safety and immunogenicity, it is critical to review clinical evidence supporting their use in IBD in order to overcome reluctance from patients and clinicians alike.
Objective:
to review clinical studies using infliximab (IFX) biosimilars in IBD.
Method:
we reviewed PubMed for original articles published up to July 1st 2017, reporting data on efficacy and/or safety of IFX biosimilars in IBD.
Results:
23 observational studies were found, 12 of them assessing switch from IFX originator to biosimilar and 17 assessing induction therapy with IFX biosimilar. Efficacy, safety and immunogenicity were compared, generally yielding similar results for originator and biosimilar IFX. So far only one randomized controlled trial assessed switching from originator to biosimilar IFX and it was not powered to show similarity in IBD. Ongoing trials are comparing IFX biosimilar and originator head to head in patients in remission, as well as switch versus reverse-switch. Current IBD clinical guidelines are discussed as well as future perspectives for biosimilars in IBD.
Conclusion:
observational studies seem to confirm biosimilarity in a real-world clinical setting. Current trials are expected to elucidate the remaining doubts about clinical biosimilarity.
More Related Videos
07:25In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
07:38Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
Published on: September 13, 2016
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drug Products: Biologics, Biosimilars and Interchangeables
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Ulcerative Colitis in IBD